Skip to main content
Premium Trial:

Request an Annual Quote

Verinata Bets on Illumina HiSeq 2000 for Non-Invasive Prenatal Aneuploidy Test


Verinata Health will use Illumina's HiSeq 2000 sequencer to commercialize its non-invasive prenatal test for the detection of multiple aneuploidies, the company said last week.

Under a three-year supply agreement, Verinata will purchase Illumina's sequencing instruments and consumables, and the two partners will collaborate in obtaining regulatory approval for the testing service.

Specifically, the supply agreement will "provide uninterrupted access" to Illumina's HiSeq 2000 and consumables, including "certain updates and improvements applied to current technology," said Verinata CEO Caren Mason in a statement.

Verinata is developing a non-invasive prenatal diagnostic test for trisomy 21 and other fetal aneuploidies, which it plans to launch later this year or in early 2012. This summer, the company raised $46.5 million in a Series C venture capital financing round (CSN 8/9/2011).

Sequenom and LifeCodexx are also developing sequencing-based prenatal tests for trisomy 21. Sequenom, which plans to launch its MaterniT21 test either later this year or early next year, signed a similar supply agreement with Illumina this summer (CSN 6/12/2011).

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.